Twelve patients with cirrhosis (nine men, three women) aged years, who were admitted consecutively with bleeding oesophageal varices, were studied three days after the bleeding had stopped. Three of these patients were studied again one month later. The As cimetidine does not affect portal pressure in patients with cirrhosis it probably does not reduce splanchnic blood flow. The possibility that it causes simultaneous vasoconstriction in the portal system to maintain portal pressure is highly unlikely. The original report' that cimetidine reduces blood flow to the liver in normal subjects has itself been challenged. In that study hepatic blood flow was measured by clearance of indocyanine green and the reduction after cimetidine interpreted as indicating decreased liver blood flow. The reduction in indocyanine green clearance after cimetidine may, however, have been caused not only by a decrease in blood flow to the liver but also by a decrease in extraction of indocyanine green. Such a decrease in extraction of indocyanine green after cimetidine has been shown in two patients with liver disease, in whom hepatic blood flow apparently increased.5 This provides further support for our conclusion that cimetidine does not have any effect on portal hypertension in patients with cirrhosis and so is unlikely to be beneficial in preventing recurrent bleeding from gastrooesophageal varices. Systemic lupus erythematosus has a variable clinical course, making assessment of treatment difficult. In association with steroids cyclophosphamide has been used to treat the disease for at least 20 years. Cyclophosphamide is claimed to reduce the dose of steroids required but is extremely toxic.
Patients, methods, and results
Twelve patients with cirrhosis (nine men, three women) aged years, who were admitted consecutively with bleeding oesophageal varices, were studied three days after the bleeding had stopped. Three of these patients were studied again one month later. The As cimetidine does not affect portal pressure in patients with cirrhosis it probably does not reduce splanchnic blood flow. The possibility that it causes simultaneous vasoconstriction in the portal system to maintain portal pressure is highly unlikely. The original report' that cimetidine reduces blood flow to the liver in normal subjects has itself been challenged. In that study hepatic blood flow was measured by clearance of indocyanine green and the reduction after cimetidine interpreted as indicating decreased liver blood flow. The reduction in indocyanine green clearance after cimetidine may, however, have been caused not only by a decrease in blood flow to the liver but also by a decrease in extraction of indocyanine green. Such a decrease in extraction of indocyanine green after cimetidine has been shown in two patients with liver disease, in whom hepatic blood flow apparently increased.5 This provides further support for our conclusion that cimetidine does not have any effect on portal hypertension in patients with cirrhosis and so is unlikely to be beneficial in preventing recurrent bleeding from gastrooesophageal varices. Cyclophosphamide is claimed to reduce the dose of steroids required but is extremely toxic.
We report on two women who developed bladder cancer after prolonged treatment with cyclophosphamide.
Case 1-A 28-year-old woman developed systemic lupus erythematosus in 1969 after exposure to sunlight. Symptoms included rash, haemolytic anaemia, and proteinuria. Renal biopsy specimens showed proliferative glomerulonephritis. Treatment was started with steroids and with cyclophosphamide 50-100 mg daily, which was given intermittently for six years. In 1981 she presented with symptoms of urinary tract infection. Cultures were sterile. Intravenous urography disclosed a bladder tumour: biopsy specimens showed poorly differentiated keratinising squamous-cell carcinoma with extensive haemorrhage and necrosis. A short course of deep x-ray treatment was followed by total cystectomy and transplantation of ureters into an ileal conduit. Kidney function remained normal with no evidence of recurrence of the systemic lupus erythematosus.
Case 2-A 45-year-old woman presented in 1969 with a five-year history of respiratory symptoms, bilateral pleural effusions, and moderate proteinuria and lupus erythematosus cells on testing. She was three months pregnant.
Renal biopsy specimen's showed proliferative glomerulonephritis. She underwent hysterotomy and tubal ligation. Prednisone 50 mg and cyclophosphamide 100 mg daily were started: both were reduced to maintenance dosage but when they were stopped joint swelling recurred.
In 1976, while taking 20 mg cyclophosphamide and 7-5 mg prednisone, she developed left loin pain. Intravenous urography showed a dilated left ureter and calices due to obstruction by bladder tumour. Investigations showed poorly differentiated transitional-cell carcinoma infiltrating muscle. She underwent deep x-ray treatment, total cystectomy, and transplantation of ureters into an ileal conduit. Renal function was normal. Four years after this operation she developed an exacerbation of systemic lupus erythematosus after exposure to sunlight. She responded satisfactorily to steroids alone.
Comment
Carcinoma of the bladder is uncommon in women aged under 40, and invasive carcinoma as found in these two patients is exceptional. Neither had been exposed to any known carcinogen other than cyclophosphamide, but both had received extensive treatment with this drug.
Since the early 1970s evidence has accumulated concerning the carcinogenic properties of cyclophosphamide.14 Accepting this association, two questions must be answered: Is it justifiable to use the drug? What follow-up should patients receive who have already received the drug? Donadia et al5 found no convincing evidence that cyclophosphamide had any beneficial effect in the treatment of lupus nephritis. It would seem unjustifiable, therefore, to continue its use in this condition.
In other autoimmune conditions and malignant disease we suggest carefully controlled trials of cyclophosphamide, assessing its benefits in each condition, and taking into account the long-term risks before it is accepted as standard treatment. Follow-up of patients who have already received the drug should be of long duration.
Symptoms of cystitis-frequency and dysuria, with or without haematuria or bacteriuria-should be taken seriously, as they are common presenting features of carcinoma of the bladder and assume even more importance in patients who have received cyclophosphamide. A skeleton regimen with individual variations would include sixmonthly visits with urological history, urine microscopy, culture, and cytology. If there is a positive response intravenous urography should be performed and, when indicated, cystoscopy. The patient should be advised not to await the next six-monthly appointment if symptoms develop but to report at the earliest opportunity. ' 
Patients, methods, and results
A total of 106 patients with Crohn's disease (mean age 41 years) and 106 patients with ulcerative colitis (mean age 46 years) who were unselected and attending a gastrointestinal clinic were studied; diagnoses were based on conventional criteria. A control group comprised 106 healthy subjects, mainly hospital employees, matched for age and sex with the patients with Crohn's disease. In all subjects anthropometric measurements were made of height, weight, mid-arm circumference (MAC), triceps skinfold thickness (TSF), and total skinfold thickness at four sites (triceps, biceps, subscapular, and suprailiac). Mid-arm muscle circumference (MAMC) was calculated from the formula MAMC=MAC-0-314 TSF.' Observed measurements were expressed as a percentage of ideal standards with the exception of total skinfold thickness, which was expressed in mm. Current smoking habits were documented in all subjects and clinical features of the disease in patients with inflammatory bowel disease.
Non-smokers in the control group and the group with ulcerative colitis were heavier than cigarette smokers and had more subcutaneous fat as determined by skinfold thickness (significant for triceps skinfold thickness in controls (p < 0-05) (table). The difference in measurements between smokers and non-smokers, however, was not evident in the patients with Crohn's disease, except that total skinfold thickness was significantly increased in cigarette smokers compared with non-smokers (p <005). Non-smokers with Crohn's disease had significantly lower values for all measurements than non-smokers in the control group and group with ulcerative colitis; these last two groups showed no difference in measurement. Although most of the measurements in cigarette smokers with Crohn's disease were lower than those in cigarette smokers in the control group and the group with colitis, none of the differences achieved significance.
Mean ± SD anthropometric measurements in non-smokers and cigarette smokers with Crohn's disease and ulcerative colitis, and in controls
